ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

Three financing initiatives announced over last three months secure combined commitments of over $100M to drive forward the Company's human cell therapy platform including its clinical-stage islet cell replacement product candidates Initial data from cl... Regenerative Medicine, Endocrinology, Venture Capital ViaCyte, islet replacement, diabetes, PEC-Direct, PEC-Encap
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news